what is semaglutide injection for weight loss 1.75mg Semaglutide Weight Loss Treatment: GLP-1

J Endocrinol (2014) 221(1):T3141

Substance Powder-based semaglutide Development phase Preclinical Temperature stability 1 0.1% degradation after 6 months 2 Administration Nasal powder (other delivery routes are explored) Leverage established manufacturing processes Spray-drying process (intranasal delivery) Partnership Seeking partnership for continued research and development Demonstrating strong preclinical performance A preclinical in-vivo study evaluated three powder-based intranasal semaglutide formulations developed with AmorphOX

The vote was advisory

Furthermore, we performed a dose-response analysis and considered different subgroups to evaluate the effects of L-carnitine on glycemic indices